Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBS10072S in Advanced Solid Tumors and Astrocytoma
NCT04430842Phase 1Completed
- Sponsor
- Quadriga BioSciences, Inc.
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QBS10072S in solid tumor (advanced stage) and astrocytoma, sponsored by Quadriga BioSciences, Inc. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2020; status: completed.
02
Drugs
QBS10072S
03
Conditions
solid tumor (advanced stage)astrocytoma
Beyond the preview
Go deeper on NCT04430842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430842.